Business Context and Reporting Period
This Form 8-K is a current report filed by AVROBIO, Inc. (not Tectonic Therapeutic, Inc., as indicated in the metadata) on June 9, 2023. The report covers events occurring on June 6, 2023, specifically regarding the 2023 Annual Meeting of Stockholders and executive compensation arrangements tied to a pending asset sale.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to specific executive transaction bonuses:
- Erik Ostrowski (President, Interim CEO, CFO, Treasurer): $150,000 transaction bonus.
- Azadeh Golipour (Chief Technology Officer): $100,000 transaction bonus.
These bonuses are conditioned upon the closing of the "Asset Sale" (sale of the cystinosis gene therapy program) and are payable in three equal installments within 90 days of closing.
Material Changes and Corporate Actions
The filing details two primary corporate actions:
- Executive Compensation: The Compensation Committee approved transaction bonuses for two officers contingent on the closing of the cystinosis gene therapy program sale. Unpaid installments are forfeited if the officers resign or are terminated prior to payment dates.
- Annual Meeting Results: Stockholders voted on director elections and auditor ratification. A quorum was present.
Guidance, Outlook, and Voting Results
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks beyond the standard contingencies of the asset sale closing. However, it provides specific voting results from the June 6, 2023, Annual Meeting:
Director Elections (Class II)
| Nominee | Votes For | Votes Withheld | Broker Non-Votes |
|---|---|---|---|
| Ian Clark | 20,810,217 | 5,332,015 | 8,660,564 |
| Annalisa Jenkins, M.B.B.S., F.R.C.P. | 16,685,601 | 9,456,631 | 8,660,564 |
Auditor Ratification
Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Votes For: 34,092,579
- Votes Against: 33,201
- Abstentions: 677,016
Investor Verification Checklist
- Verify the closing status of the cystinosis gene therapy program "Asset Sale" to determine if the executive bonuses are payable.
- Confirm the final composition of the Board of Directors following the election of Ian Clark and Annalisa Jenkins.
- Review the definitive agreement for the Asset Sale to understand the specific conditions and timeline for the transaction.
- Note the discrepancy between the metadata company name (Tectonic Therapeutic) and the actual registrant (AVROBIO, Inc.).